BNTC

Benitec Biopharma Inc. (BNTC) - Q1 2026 (Ended Sept 30, 2025) Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. Benitec Biopharma Inc. is a clinical-stage biotechnology company developing novel genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform. The Company's lead candidate, BB-301, is an AAV-based gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). The Company operates as a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.

Key Financial Metrics

Note: The Company reported no debt or borrowings as of September 30, 2025. Interest income of $1.011 million contributed to other income.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately 77% to $8.965 million, driven primarily by a significant rise in General and Administrative (G&A) expenses.
• G&A Expense Surge: G&A expenses jumped from $2.2 million to $6.4 million. Management attributes this increase primarily to a $4.0 million rise in share-based compensation expense and a $267,000 increase in salaries and wages.
• R&D Stability: R&D expenses decreased slightly to $3.37 million from $3.58 million, reflecting the timing of contract manufacturing activities and payments for the OPMD Natural History and Dosing study.
• Share Count: The weighted average number of shares outstanding increased significantly to 41.5 million (from 27.9 million in the prior year) due to the inclusion of pre-funded warrants in the basic EPS calculation following a correction of an immaterial error.

Outlook, Management Commentary, and Risks

• Clinical Progress: On November 3, 2025 (subsequent to the period end), the Company announced positive interim results for the BB-301 Phase 1b/2a trial. All six patients in Cohort 1 met statistical criteria for response (100% response rate), leading to the FDA granting Fast Track Designation for BB-301.
• Liquidity: As of September 30, 2025, the Company held $94.5 million in cash. Management estimates this is sufficient to fund operations for at least the next twelve months. No sales were made under the $75 million At-The-Market (ATM) agreement during the quarter.
• Subsequent Financing: On November 5, 2025, the Company completed a public offering and concurrent direct offering, raising approximately $100 million in gross proceeds.
• Internal Controls: The Company disclosed a material weakness in internal controls over financial reporting related to the review process for share-based compensation calculations. Remediation efforts are underway, including system updates and enhanced review processes.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, dependence on third-party manufacturers, and the ability to remediate the identified material weakness in internal controls.

Investor Verification Checklist

• Share-Based Compensation: Verify the magnitude of the $4.0 million increase in share-based compensation within G&A and its impact on future burn rates.
• Cash Runway: Confirm the updated cash runway following the $100 million financing completed in November 2025.
• Internal Control Remediation: Monitor the timeline and effectiveness of the remediation plan for the material weakness in share-based compensation controls.
• Clinical Data: Review the full interim data release for BB-301 to validate the 100% response rate and safety profile cited in the Fast Track designation.
• Warrant Dilution: Assess the dilution impact of the 20.4 million outstanding warrants and the recent issuance of new shares in the November offering.